Lexicon Pharmaceuticals
LXRX
1.73
-0.04
-1.99%
Lexicon Pharmaceuticals
US · LXRX
#3430 by market cap
1.73
-0.04
-1.99%
Live - 5344 symbols - heartbeat 289s ago
· 2026-10-08 09:59
Pre-market
1.75
-0.57%
After-hours
1.76
0.00%
Overnight
1.78
+1.14%
- Market cap
- 767.55M
- P/E (TTM)i
- -10.78
- P/Bi
- 4.40
- EPSi
- -0.14
- Div yieldi
- 0.00%
- 52W posi
- 40%
Reader sentiment
Are you bullish or bearish on LXRX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -9.40, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +60.24% YoY
Margins
- Gross margin
- 99.45%
- Operating margin
- -98.21%
- Net margin
- -101.08%
Key ratios & quality
- Enterprise valuei
- 726.96M
- Altman Z-Scorei
- -9.40
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 63.21M | 322.07M | 24.00M | 298.00K | 139.00K | 1.20M | 31.08M | 49.80M |
| Gross profit | 60.72M | 318.84M | 22.07M | 298.00K | 139.00K | 1.12M | 30.47M | 49.53M |
| Selling & admin expenses | 63.75M | 56.84M | 47.23M | 32.34M | 48.08M | 113.98M | 143.10M | 37.32M |
| Research & development | 100.24M | 91.92M | 153.62M | 55.05M | 52.82M | 58.89M | 84.48M | 61.12M |
| Operating profit | -103.28M | 170.08M | -178.79M | -87.09M | -100.76M | -171.75M | -197.12M | -48.91M |
| Pretax profit | -120.55M | 124.12M | -58.57M | -87.76M | -101.94M | -177.12M | -200.40M | -50.34M |
| Tax | 0 | -6.01M | -- | -- | -- | -- | -- | -- |
| Net profit | -120.55M | 130.13M | -58.57M | -87.76M | -101.94M | -177.12M | -200.40M | -50.34M |
| Basic EPS | -1 | 1 | -1 | -1 | -1 | -1 | -1 | 0 |
| Diluted EPS | -1.14 | 1.16 | -0.53 | -0.60 | -0.62 | -0.80 | -0.63 | -0.14 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.26M | 28.87M | 14.18M | 5.49M | 21.10M | 692.00K |
| Gross profit | 1.23M | 28.83M | 14.17M | 5.29M | 20.99M | 653.00K |
| Selling & admin expenses | 11.61M | 9.35M | 7.60M | 8.76M | 9.23M | 9.75M |
| Research & development | 15.30M | 15.75M | 18.76M | 11.32M | 12.76M | 17.44M |
| Operating profit | -25.68M | 3.74M | -12.19M | -14.78M | -996.00K | -26.54M |
| Pretax profit | -25.30M | 3.25M | -12.77M | -15.53M | -1.04M | -31.78M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -25.30M | 3.25M | -12.77M | -15.53M | -1.04M | -31.78M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.07 | 0.01 | -0.04 | -0.04 | 0.00 | -0.07 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 173.32M | 337.75M | 157.72M | 88.92M | 140.87M | 176.55M | 246.19M | 101.90M |
| Cash & ST investments | 160.05M | 271.66M | 152.28M | 86.74M | 138.36M | 170.03M | 237.96M | 96.23M |
| Inventory | 4.68M | 4.24M | -- | -- | 0 | 381.00K | 231.00K | 281.00K |
| Total assets | 284.14M | 417.72M | 203.79M | 136.91M | 194.30M | 229.43M | 298.42M | 184.99M |
| Total current liabilities | 36.75M | 65.34M | 46.81M | 22.12M | 23.17M | 31.55M | 45.25M | 20.87M |
| Short-term debt | 1.12M | 11.57M | 12.20M | 1.09M | 1.29M | 1.29M | 1.18M | 6.24M |
| Long-term debt | 243.89M | 234.17M | -- | -- | 48.58M | 99.51M | 100.30M | 49.41M |
| Total liabilities | 310,541,000.00 | 300,614,000.00 | 47,417,000.00 | 23,314,000.00 | 77,175,000.00 | 136,319,000.00 | 152,470,000.00 | 77,449,000.00 |
| Total equity | -26.41M | 117.10M | 156.37M | 113.60M | 117.12M | 93.11M | 145.95M | 107.54M |
| Retained earnings | -1.47B | -1.34B | -1.40B | -1.49B | -1.59B | -1.77B | -1.97B | -2.02B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 245.81M | 145.08M | 122.53M | 101.90M | 186.03M | 196.58M |
| Cash & ST investments | 194.84M | 139.01M | 115.95M | 96.23M | 170.66M | 190.61M |
| Inventory | 201.00K | 168.00K | 158.00K | 281.00K | 276.00K | 1.20M |
| Total assets | 297.67M | 225.58M | 205.93M | 184.99M | 268.82M | 250.06M |
| Total current liabilities | 110.69M | 34.84M | 21.72M | 20.87M | 9.90M | 14.71M |
| Short-term debt | 43.10M | 909.00K | 1.64M | 6.24M | 1.64M | 1.64M |
| Long-term debt | 58.64M | 56.11M | 56.51M | 49.41M | 49.68M | 51.44M |
| Total liabilities | 174,639,000.00 | 96,143,000.00 | 85,768,000.00 | 77,449,000.00 | 65,963,000.00 | 75,535,000.00 |
| Total equity | 123.03M | 129.44M | 120.16M | 107.54M | 202.86M | 174.53M |
| Retained earnings | -1.99B | -1.99B | -2.00B | -2.02B | -2.02B | -2.05B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -148.61M | 113.81M | -142.97M | -87.02M | -88.85M | -161.90M | -178.78M | -67.85M |
| Depreciation & amortization | 3.68M | 3.65M | 2.93M | 292.00K | 427.00K | 554.00K | 534.00K | 621.00K |
| Free cash flow | -148.70M | 113.74M | -143.06M | -88.24M | -90.18M | -162.37M | -179.81M | -67.85M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -240.00K | -941.00K | 68.94M | 34.41M | 93.34M | 138.00M | -1.73M | -572.00K |
| Ending cash balance | 80.39M | 36.11M | 126.26M | 64.07M | 46.35M | 22.47M | 66.66M | 63.33M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -43.78M | 16.99M | -23.83M | -17.23M | -14.73M | -9.19M |
| Depreciation & amortization | 176.00K | 176.00K | 151.00K | 118.00K | 110.00K | 102.00K |
| Free cash flow | -43.78M | 16.99M | -23.83M | -17.23M | -14.73M | -9.19M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | -572.00K | 0 | 70.05M | 1.02M |
| Ending cash balance | 62.89M | 50.36M | 78.66M | 63.33M | 67.09M | 40.92M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -938.23 | 286.97 | -42.84 | -65.01 | -88.37 | -168.50 | -167.66 | -39.72 |
| ROA %i | -33.45 | 37.08 | -18.85 | -51.52 | -61.56 | -83.60 | -75.93 | -20.83 |
| ROIC %i | -40.00 | 49.07 | -17.57 | -61.10 | -69.90 | -92.44 | -86.93 | -23.03 |
| 5-year avg ROE %i | -158.02 | -91.79 | -100.03 | -101.17 | -97.04 | -15.55 | -106.48 | -105.85 |
| EBIT margin %i | -157.84 | 44.96 | -183.50 | -29,179.87 | -71,341.01 | -13,622.76 | -594.65 | -84.34 |
| FCF / sales %i | -- | 35.31 | -- | -- | -- | -- | -- | -- |
| Current ratioi | 4.72 | 5.17 | 3.37 | 4.02 | 6.08 | 5.60 | 5.44 | 4.88 |
| Quick ratioi | 4.52 | 5.02 | 3.26 | 3.92 | 5.97 | 5.42 | 5.34 | 4.73 |
| Debt / assetsi | 86.23 | 58.83 | 6.29 | 1.66 | 28.46 | 46.23 | 36.32 | 33.96 |
| LT debt / equityi | -- | 199.97 | 0.39 | 1.05 | 46.11 | 112.53 | 73.46 | 52.62 |
| Interest coveragei | -4.80 | 7.00 | -3.03 | -108.42 | -35.67 | -12.52 | -11.86 | -5.04 |
| Revenue CAGR (3Y) %i | -21.37 | 59.58 | -36.04 | -83.23 | -92.44 | -63.12 | 370.72 | 610.25 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -86.09 | -65.30 | -45.92 | -39.72 | -16.01 | -40.21 |
| ROA %i | -49.60 | -40.28 | -26.02 | -20.83 | -9.21 | -25.70 |
| ROIC %i | -57.26 | -44.90 | -29.20 | -23.03 | -9.98 | -28.01 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -528.10 | -184.91 | -82.43 | -84.34 | -25.84 | -127.16 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 2.22 | 4.16 | 5.64 | 4.88 | 18.79 | 13.37 |
| Quick ratioi | 2.19 | 4.05 | 5.45 | 4.73 | 18.43 | 13.07 |
| Debt / assetsi | 34.18 | 25.28 | 28.24 | 33.96 | 21.47 | 23.71 |
| LT debt / equityi | 47.66 | 43.35 | 47.03 | 52.62 | 27.64 | 33.03 |
| Interest coveragei | -13.22 | -8.59 | -5.75 | -5.04 | -2.22 | -6.29 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Discovery, development and commercialization of pharmaceutical products for the treatment of human100.00%
Quote time 2026-10-08 09:59:25 · For reference only, not investment advice and not tailored to your situation.